Privacy policy
Prepared by: Research Desk. Sources are linked for verification.
This policy explains what data KlowSignal handles and why.
Who runs this site
KlowSignal is published by the KlowSignal Research Desk. Contact: info@zvezdaff.com.
Data collected
The site has no accounts, comment forms or newsletter signups, and it does not ask visitors for personal information. It does not use advertising cookies and does not sell personal data.
The site is hosted on Framer. Like any web host, Framer processes the technical data needed to deliver pages, such as IP address, browser type and the pages requested, and it may produce aggregated visit statistics.
Links to other websites
Pages link to external sources such as PubMed and the FDA, and to Purita through paid links. A paid link carries a tracking code that Purita's website can record when the link is followed. Other websites apply their own privacy policies.
Messages sent to info@zvezdaff.com are used only to reply. Addresses are not added to any mailing list or shared.
Access and deletion
Requests to access, correct or delete personal data can be sent to info@zvezdaff.com.
Changes
Last updated: 21 October 2026.
More from KlowSignal
How to read a research or regulatory signal
What a cell study, a phase 3 trial, a press release or an FDA list entry can and cannot tell you, with key regulatory vocabulary and a checklist for each signal.
FDA compounding committee, July 2026: seven research peptides on the agenda
FDA's Pharmacy Compounding Advisory Committee agenda for 23–24 July 2026 lists BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. Here is what the record says.
Elamipretide (SS-31): the 2025 accelerated approval on the record
SS-31 is a Szeto-Schiller tetrapeptide studied for its binding to cardiolipin. In September 2025 FDA granted accelerated approval to elamipretide for Barth syndrome. Here is what the record shows.